A BILL TO AMEND THE SOUTH CAROLINA CODE OF LAWS BY AMENDING SECTION 40-43-60, RELATING TO MISCELLANEOUS REQUIREMENTS CONCERNING PHARMACIES AND THE PRACTICE OF PHARMACY, SO AS TO PROVIDE PHARMACIES PERMITTED IN THIS STATE SHALL COOPERATE WITH FEDERAL AND STATE ACQUISITION COST SURVEYS; AND BY ADDING SECTION 38-71-2270 SO AS TO PROVIDE GUIDELINES FOR PHARMACY BENEFITS MANAGERS WHEN REIMBURSING PHARMACIES AND PHARMACISTS FOR PRESCRIPTION DRUGS AND PHARMACY SERVICES.
Impact
The bill's implications on state laws would establish specific guidelines and protections for pharmacies regarding reimbursement amounts for services rendered. By requiring that reimbursements meet or exceed NADAC and the current South Carolina Medicaid dispensing fee, the bill aims to enhance the financial viability of pharmacies. The potential for pharmacies to file complaints with the Department of Insurance further supports their rights and seeks to ensure accountability from PBMs in their financial practices.
Summary
House Bill 4791 seeks to amend various sections of the South Carolina Code of Laws, specifically focusing on the requirements concerning pharmacies and their cooperation with federal and state acquisition cost surveys. The bill mandates that pharmacies with proper permits must align with the National Average Drug Acquisition Cost (NADAC) and outlines the expected reimbursement practices from pharmacy benefits managers (PBMs). This legislative effort is part of a broader initiative to ensure fair practices in the pharmacy industry, especially concerning the pricing of prescription drugs and pharmacy services.
Contention
One notable point of contention surrounding HB 4791 may involve the operational realities and economic impacts on pharmacy benefits managers as they adjust to the new reimbursement requirements. While proponents argue that the bill offers needed protections for pharmacies ensuring they do not receive below-cost reimbursements, opponents may raise concerns about the administrative burden this creates on PBMs and potential ripple effects throughout the healthcare system. The balance between equitable reimbursement for pharmacies and the operational flexibility of PBMs could provoke discussion among stakeholders in the pharmacy and insurance sectors.